We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
-5.66%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$108M
AUM Growth
-$175M
Cap. Flow
-$179M
Cap. Flow %
-165.02%
Top 10 Hldgs %
92.43%
Holding
31
New
6
Increased
13
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.59M
2
MTEM
Molecular Templates, Inc.
MTEM
+$2.79M
3
SCYX icon
SCYNEXIS
SCYX
+$2.02M
4
KALA icon
KALA BIO
KALA
+$640K
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$489K

Top Sells

Rank Stock Value
1
LITS
Lite Strategy Inc
LITS
+$2.95M
2
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$763K
3
BBDC icon
Barings BDC
BBDC
+$302K
4
GARS
Garrison Capital Inc.
GARS
+$50.5K
5
MRKR icon
Marker Therapeutics
MRKR
+$26.9K

Sector Composition

Rank Sector Weight
1 Healthcare 60.25%
2 Financials 9.15%
3 Real Estate 1.4%
4 Utilities 0.96%
5 Industrials 0.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBBP
1
DELISTED
Strongbridge Biopharma plc.
SBBP
$30.5M 28.22%
6,294,789
+896,755
+17% +$4.59M
LITS
2
Lite Strategy Inc
LITS
$33M
$15.9M 14.66%
183,930
-36,092
-16% -$2.95M
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$14.9M 13.78%
51,279
-658,821
-93% -$188M
GARS
4
DELISTED
Garrison Capital Inc.
GARS
$9.21M 8.52%
1,112,517
-6,012
-0.5% -$50.5K
MTEM
5
DELISTED
Molecular Templates, Inc.
MTEM
$8.62M 7.97%
106,616
+36,364
+52% +$2.79M
ICMB icon
6
Investcorp Credit Management BDC
ICMB
$12.4M
$7.7M 7.12%
901,439
+7,001
+0.8% +$62.7K
SCYX icon
7
SCYNEXIS
SCYX
$44.5M
$5.19M 4.8%
54,063
+17,125
+46% +$2.02M
AMLP icon
8
Alerian MLP ETF
AMLP
$12.7B
$4.47M 4.13%
83,683
-138
-0.2% -$7.44K
BRK.B icon
9
Berkshire Hathaway Class B
BRK.B
$1.06T
$1.99M 1.84%
9,312
– –
JBGS
10
JBG SMITH
JBGS
$877M
$1.52M 1.4%
41,170
– –
PCG icon
11
PG&E
PCG
$38.6B
$1.03M 0.96%
22,500
– –
UHAL icon
12
U-Haul Holding Co
UHAL
$14.1B
$963K 0.89%
27,000
– –
MRKR icon
13
Marker Therapeutics
MRKR
$22.3M
$738K 0.68%
8,154
-313
-4% -$26.9K
KURA icon
14
Kura Oncology
KURA
$967M
$607K 0.56%
34,708
+18,293
+111% +$351K
ACRS icon
15
Aclaris Therapeutics
ACRS
$749M
$577K 0.53%
39,755
+20,241
+104% +$347K
ARQL
16
DELISTED
Arqule Inc
ARQL
$511K 0.47%
90,254
+77,295
+596% +$440K
KALA icon
17
KALA BIO
KALA
$15.7M
$506K 0.47%
+21
New +$640K
CTIC
18
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$427K 0.39%
+197,459
New +$489K
INDP icon
19
Indaptus Therapeutics
INDP
$337M
$364K 0.34%
29
– –
ABDC
20
DELISTED
Alcentra Capital Corp
ABDC
$345K 0.32%
57,677
+2,318
+4% +$14.5K
EIGR
21
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$306K 0.28%
+850
New +$291K
CPRX
22
DELISTED
Catalyst Pharmaceutical
CPRX
$276K 0.26%
72,967
+39,166
+116% +$123K
FSTX
23
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$253K 0.23%
+5,247
New +$263K
FPAC.U
24
DELISTED
Far Point Acquisition Corporation Units, each consisting of one share of Class A common stock, $0.00
FPAC.U
$237K 0.22%
23,030
+926
+4% +$9.44K
DRNA
25
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$225K 0.21%
+14,724
New +$214K
1
2

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q3 2018 Portfolio in Review

As of Q3 2018, Caxton Corporation held 31 positions worth $108M, down 62% from $283M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Caxton Corporation withdrew a net $179M in Q3 2018, closing 2 positions and reducing 5 holdings. Its most notable exit was Oncternal Therapeutics, Inc. Common Stock, an estimated $763K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 22% a quarter earlier, followed by Financials and Real Estate.

Against the trend, Caxton Corporation opened a new position in KALA BIO worth $506K.

  • Caxton Corporation's largest Q3 2018 buy was KALA BIO: 21 shares worth $506K.
  • Caxton Corporation added most to Strongbridge Biopharma plc. in Q3 2018, an estimated $4.59M increase.
  • Caxton Corporation's biggest Q3 2018 reduction was Lite Strategy Inc, cutting an estimated $2.95M.
  • Caxton Corporation fully exited Oncternal Therapeutics, Inc. Common Stock in Q3 2018, selling an estimated $763K.
  • Caxton Corporation's ten largest holdings make up 92% of its $108M portfolio in Q3 2018.
  • Caxton Corporation opened 6 new positions and closed 2 in Q3 2018.
  • Caxton Corporation's portfolio value fell 62% quarter-over-quarter to $108M.

Based on Caxton Corporation's 13F filing for Q3 2018, filed 14 Nov 2018.